Sign in

    Dylan Chu • Point72 Hong Kong

    Dylan Chu is an Analyst at Point72 Hong Kong specializing in asset management, with a track record of covering companies such as Zepp Health Corp. Since joining Point72 in July 2020 after previously working at CLSA Limited, where he focused on advising on securities, Chu has actively engaged in company analysis and earnings call discussions to inform investment decisions. His professional credentials include a Representative license for asset management under the Securities and Futures Commission (SFC) of Hong Kong, reflecting expertise in both research and asset management roles. Chu's analytical contributions have been featured in company earnings calls and public financial disclosures.

    Dylan Chu's questions to Zepp Health Corp (ZEPP) leadership

    Dylan Chu's questions to Zepp Health Corp (ZEPP) leadership • Q2 2025

    Question

    Dylan Chu of Point72 Hong Kong asked about the expected sales contribution and gross margin profile for the new HelioStripe, the company's medium-term gross margin targets, and the timeline for resolving the product's supply constraints.

    Answer

    CFO Leon Cheng Deng highlighted that the HelioStripe, launched in June, is gaining significant traction and currently faces more demand than supply. He noted it carries a healthy gross margin comparable to the company average. Looking ahead, Deng stated that as the product mix shifts towards more premium devices, the company expects gross margins to expand beyond its current 40% target over the next two to three years. He also confirmed that the supply constraints for the HelioStripe are expected to be resolved during Q3 2025.

    Ask Fintool Equity Research AI

    Dylan Chu's questions to Zepp Health Corp (ZEPP) leadership • Q2 2025

    Question

    The analyst asked about the expected sales contribution and gross margin of the new HelioStripe, the medium-term (2-3 year) gross margin outlook, and the timeline for resolving the HelioStripe's supply constraints.

    Answer

    Management stated that the HelioStripe, launched in June, is a popular and high-margin product that is currently supply-constrained, with the issue expected to be resolved in Q3. They anticipate the overall product mix will continue to improve, pushing the medium-term gross margin above the current 40% target.

    Ask Fintool Equity Research AI